Watson and Crick 50 years on. From double helix to pharmacogenomics

Anaesthesia

Volumn 59, Issue 2, 2004, Pages 150-165

  Sweeney, B P ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Anaesthesia; Genome; Pharmacogenomics

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTILEUKEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CODEINE; CYTOCHROME P450; DIAZEPAM; DNA; DROPERIDOL; ENCAINIDE; FLECAINIDE; HALOPERIDOL; MERCAPTOPURINE; METOPROLOL; MORPHINE; NEUROLEPTIC AGENT; OMEPRAZOLE; ONDANSETRON; PROPAFENONE; PROPRANOLOL; SEROTONIN 3 ANTAGONIST; THIORIDAZINE; TRAMADOL; TROPISETRON; UNINDEXED DRUG; WARFARIN;

BIOINFORMATICS; CANCER; DEPRESSION; DNA HELIX; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOXICITY; DRUG TRANSPORT; GENE; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE TARGETING; GENETIC CODE; GENETIC REGULATION; GENOME; GENOMICS; HEART ARRHYTHMIA; HUMAN; HUMAN GENOME; INTENSIVE CARE; JAUNDICE; LEGAL ASPECT; LEUKEMIA; MEDICAL ETHICS; MEDICAL GENETICS; MOLECULAR BIOLOGY; NEUROPATHY; NONHUMAN; PAIN; PHARMACOGENOMICS; PHILOSOPHY; PREDICTION; PSYCHOSIS; RACE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOCIAL ASPECT;

DNA; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMAN GENOME PROJECT; HUMANS; MOLECULAR BIOLOGY; PHARMACOGENETICS; TERMINOLOGY;

EID: 0442278352     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2004.03570.x     Document Type: Review

References (71)

1. Watson JD, Crick FHC. Molecular structure of nucleic acids. Nature 1953; 171: 737-8.
2. Schroedinger E. What is Life? Cambridge: Cambridge University Press, 1944.
3. Brown TA. Synthesis and processing of RNA. In: Genomes, 2nd edn. Oxford: BIOS, 2002: 274-308.
4. Ullrich B, Ushkaryov YA, Sudhof TC. Cartography of neurexins. More isoforms generated by alternative splicing and expressed in subsets of neurons. Neuron 1995; 14: 497-507.
5. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837-46.
6. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. Journal of the American Medical Association 2001; 286: 2296-307.
7. Brown TA. Genome anatomies. In: Genomes, 2nd edn. Oxford: BIOS, 2002: 29-66.
8. Brown TA. Mapping genomes. In: Genomes, 2nd edn. Oxford: BIOS, 2002: 154-5.
9. Mullis KB. The unusual origins of the polymerase chain reaction. Scientific American 1990; 262: 56-65.
10. Adams MA, Celniker SE, Holt RA. The genome sequence of Drosophila melanogaster. Science 2000; 287: 2185-95.
11. The C. elegans Sequencing Consortium (CESC). Genome sequence of the nematode C. elegans. A platform for investigating biology. Science 1998; 282: 2012-18.
12. The Arabidopsis Genome Initiative (AGI). Analysis of the genome sequence of the flowering plant Arabidopsis thaliana. Nature 2000; 408; 796-815.
13. Goffeau A, Barrell BG, Bussey H. Life with 6000 genes. Science 1996; 274: 562-76.
14. Venter JC, Adams MD, Myers EW. The sequence of the human genome. Science 2001; 291: 1304-51.
15. International Human Genome Sequencing Consortium (IHGSC). Initial sequencing of the human genome. Nature 2001; 409: 860-921.
16. Evans WE, Johnson JA. Pharmacogenetics: The inherited basis for individual differences in drug response. Annual Review of Human Genetics 2001; 2: 9-39.
17. Masood E. A consortium plans free SNP map of human genome. Nature 1999; 398: 545-6.
18. The International SNP Map Working Group (SNP Group). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-33.
19. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
20. Carsen PE, Flanagan CL, Iokes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484-5.
21. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128: 281-5.
22. Poulsen L, Brosen K, Arendt-Nielsen L. Codeine and morphine in extensive and poor metabolisers of sparteine: Pharmacokinetics, analgesic effects and side effects. European Journal of Clinical Pharmacology 1996; 51: 289-95.
23. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: Getting personal. American Journal of Human Genetics 1998; 63: 11-16.
24. Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; 2: 576.
25. Vogel F. Moderne Probleme der humangenetik. Ergebnisse der Inneren. Medizin und Kinderheilkunde 1959; 12: 52-125.
26. Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
27. Miksys SL, Tyndale RF. Drug metabolising cytochrome P450 in the brain. Journal of Psychiatry and Neuroscience 2002; 27: 406-15.
28. Pelkonen O, Maenpa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998; 28: 1203-53.
29. Poolsup NLI, Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics 2000; 25: 197-220.
30. Slaughter RL, Edwards DJ. Recent advances in the P450 enzymes. Annals of Pharmacotherapy 1995; 29: 619-24.
31. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolisers of the debrisoquine/sparteine polymorphism. American Journal of Human Genetics 1991; 48: 943-50.
32. Broly F, Gaedigk A, Heim M, Eichelbaum M, Kroemer HK. Debrisoquine/sparteine hydroxylation genotype and phenotype. Analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology 1991; 10: 545-58.
33. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a European population: Allele frequencies and phenotypic consequences. American Journal of Human Genetics 1997; 60: 284-95.
34. Yue Q, Alm C, Svensson J, Sawe J. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Therapeutic Drug Monitoring 1997; 19: 539-42.
35. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Current Drug Metabolism 2002; 3: 289-309.
36. Aithal GP, Day CP, Leathart JBS. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-18.
37. Sweeney B. Do genes influence outcome from anaesthesia? Editorial. British Journal of Anaesthesia 2003; 90: 725-7.
38. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. Journal of the National Cancer Institute 2000; 92: 1295-302.
39. Hoffmeyer S, Burk O Von Richter. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the USA 2000; 28: 3473-8.
40. Bond C, LaForge KS, Tian M et al. Single nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity. Possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the USA 1998; 95: 9608-13.
41. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P et al. Oestrogen-receptor-alpha gene polymorphisms affect response in bone mineral density to oestrogen in postmenopausal women. Clinical Endocrinology 2000; 52: 581-5.
42. Makoff AJ, Graham JM, Arranz MJ et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000; 10: 43-8.
43. Smeraldi E, Zenardi R, Benedetti F, Di Bella D. Polymorphisms within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 1998; 3: 508-11.
44. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Human Mutation 2000; 15: 410-17.
45. Doris PA. Hypertension genetics: Single nucleotide polymorphisms and the common disease: Common variant hypothesis. Hypertension 2002; 39: 323-31.
46. Ohmichi N, Iwai N, Uchida Y. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. American Journal of Hypertension 1997; 10: 951-5.
47. Iwa N, Ohmichi N, Nakamura Y. DD genotype of the angiotensin converting enzyme gene is a factor for left ventricular failure. Circulation 1994; 90: 2622-8.
48. Aziz I, Hall IP, McFarlane LC, Lipworth BJ. Beta-2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Journal of Allergy and Clinical Immunology 1998; 101: 337-41.
49. Weir TD, Mallek N, Sandford AJ et al. Beta2-adrenergic receptor haplotypes in mild, moderate, and fatal/near fatal asthma. American Journal of Respiratory and Critical Care Medicine 1993; 158: 787-91.
50. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta-2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Journal of Clinical Investigation 1997; 100: 3184-8.
51. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. Journal of Clinical Investigation 1997; 99: 1130-7.
52. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetetics 1999; 22: 168-70.
53. Hansen T, Echwald SM, Hansen L et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47: 598-605.
54. Cichon S, Nöthen MM, Rietsche M, Propping P. Pharmacogenetics of schizophrenia. American Journal of Medical Genetics 2000; 97: 98-106.
55. Stumm G, Russ A, Nehls M. Deductive genomics. A functional approach to identify innovative drug targets in the post-genomic era. American Journal of Pharmacogenomics 2002; 2: 263-71.
56. Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-41.
57. Spracklin DK, Hankins DC, Fisher JM et al. Cytochrome P4502E1 is the principle catalyst of human oxidative halothane metabolism in vitro. Journal of Pharmacology and Experimental Therapeutics 1997; 281: 400-11.
58. Gonzalez FJ. The use of gene-knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicology Letters 2001; 120: 199-208.
59. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology. The advent of toxicogenomics. Molecular Carcinogenesis 1999; 24: 153-9.
60. Storck T, Von Brevern MC, Behrens CK, Scheel J, Bach A. Transcriptomics in predictive toxicology. Current Opinion in Drug Discovery 2002; 5: 90-7.
61. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1997; 282: 1608-14.
62. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
63. Benowitz NL, Peres-Stable SJ, Herrera B, Jacob P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. Journal of the National Cancer Institute 2002; 94: 108-15.
64. Zebetian CP, Gelernter J, Cubells JF. Functional variants at CYP2A6: New genotyping methods, population genetics, and relevance to studies of tobacco dependence. American Journal of Medical Genetics 2000; 96: 638-45.
65. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bio-availability and decreases smoking. Clinical Pharmacology and Therapeutics 2000; 68: 35-43.
66. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Rautalahti M. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 2000; 10: 5-10.
67. Sweeney BP. Why are smokers protected against PONV? Editorial. British Journal of Anaesthesia 2002; 89: 1-4.
68. Kawajiri K, Watanabe J, Eguchi H. Genetic polymorphisms of drug-metabolising enzymes and lung cancer susceptibility. Pharmacogenetics 1995; 5: S70-3.
69. Searls DB. Bioinformatics tools to study genes and genomes. Nature 2000; 405: 177-8.
70. Lipton P. Pharmacogenetics: The ethical issues. Pharmacogenomics Journal 2003; 3: 14-16.
71. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: The promise of personalised medicine. AAPS Pharmaceutical Science 2000; 2: 30-7.